4 news items
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
VERV
8 May 24
nanoparticle (LNP) to access liver cells using either the asialoglycoprotein receptor (ASGPR) or the low-density lipoprotein receptor (LDLR
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
VERV
7 May 24
the PCSK9 gene. In addition, VERVE-102 uses a proprietary GalNAc-LNP delivery technology which allows lipid nanoparticles to access and deliver
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
BEAM
LLY
VERV
2 Apr 24
into a collaboration and license agreement in April 2019, under which Verve received exclusive access to Beam’s base editing, gene
Verve Therapeutics Announces Updates on its PCSK9 Program
VERV
2 Apr 24
, the incorporation of GalNAc allows the LNP in VERVE-102 to access liver cells using either the asialoglycoprotein receptor (ASGPR) or the low-density lipoprotein
- Prev
- 1
- Next